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Abstract. Fasudil, a Rho kinase (ROCK) inhibitor, effectively
inhibits disease severity in a mouse model of Alzheimer's
disease (AD). However, given its significant limitations,
including a relatively narrow safety window and poor oral
bioavailability, Fasudil is not suitable for long‑term use.
Thus, screening for ROCK inhibitor(s) that are more efficient,
safer, can be used orally and suitable for long‑term use in the
treatment of neurodegenerative disorders is required. The main
purpose of the present study is to explore whether FSD‑C10,
a novel ROCK inhibitor, has therapeutic potential in amyloid
precursor protein/presenilin‑1 transgenic (APP/PS1 Tg) mice,
and to determine possible mechanisms of its action. The
results showed that FSD‑C10 effectively improved learning
and memory impairment, accompanied by reduced expression
of amyloid‑β 1‑42 (Aβ1‑42), Tau protein phosphorylation (P‑tau)
and β ‑site APP‑cleaving enzyme in the hippocampus and
cortex area of brain. In addition, FSD‑C10 administration
boosted the expression of synapse‑associated proteins, such
as postynaptic density protein 95, synaptophsin, α‑amino
3‑hydroxy‑5‑methyl‑4‑isoxa‑zolep‑propionate receptor and
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neurotrophic factors, e,g., brain‑derived neurotrophic factor
and glial cell line‑derived neurotrophic factor. Taken together,
our results demonstrate that FSD‑C10 has therapeutic potential
in the AD mouse model, possibly through inhibiting the
formation of Aβ1‑42 and P‑tau, and promoting the generation of
synapse‑associated proteins and neurotrophic factors.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder
that occurs mainly in old age; it is characterized by deposits
of amyloid‑β (Aβ) plaques and neurofibrillary tangles, and
neuronal loss (1), and its prevalence is rapidly increasing.
It is likely that AD has multiple etiologies, although its
precise cause remains unknown (2). A β and tau proteins
constitute a prime neurotoxic component of senile plaques
in the brain of AD patients, thus contributing to learning
and memory impairment due to synaptic dysfunction and
neuronal degeneration (3). However, to date most therapeutic
interventions aimed at modifying a single pathological factor
(e.g., cholinergic dysfunction, or Aβ aberrant processing) have
failed because they target only limited pathogenic factors
of AD (4). Inflammation, mitochondrial dysfunction, and
oxidative stress are considered the most prominent concomitant
pathological events (5‑7), being potential targets of therapeutic
intervention. Recently, the ER‑associated degradation (ERAD)
pathway has also been drawing widespread attention as control
of protein‑folding intermediaries in AD (8,9).
Inflammation has been proposed as a main factor in the
pathogenesis of AD, including microglial activation, reactive
astrocytes and inflammatory molecules (2,10‑12). However,
it has been noted that microglial activation exhibits both
beneficial and detrimental effects depending on the stage of
microglia (13). The conversion of microglia from detrimental
(M1) to beneficial (M2) phenotype may contribute to an
anti‑inflammatory microenvironment in the brain (14). Similar
to microglia, astrocytes also contribute to neuroinflammation in AD by releasing inflammatory cytokines and other
toxic molecules (15). The ubiquitin‑proteasome system and
autophagy mechanisms are impaired due to the toxic effects of
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Aβ and oxidative stress damage, leading to the accumulation
of oxidized/unfolded proteins that may contribute to neuronal
loss (16). In fact, non‑steroidal anti‑inflammatory drugs
(NSAIDS) initially garnered enthusiasm from pre‑clinical
and epidemiologic studies as agents for reducing the risk of
AD (17), but anti‑inflammatory treatment failed to produce
beneficial effects in patients with severe cognitive impairment
and dementia (18).
It has been reported that Rho activity, which is thought to
contribute to AD pathogenesis (19), was elevated in the brain
of AD model mice (20). Pharmacologic inhibition of Rho
kinase (ROCK) induced protein degradation by autophagy in
mammalian cells (21), and suppressed Aβ production in an AD
mouse model (22), highlighting ROCK as a therapeutic target
to combat Aβ production in AD. Fasudil, a selective ROCK
inhibitor, increased dendrite branching and stabilized dendrite
arbors in CA1 pyramidal neurons of APP/PS1 mice (23) by
preventing neurodegeneration and stimulating neuroregeneration in various neurological disorders (19). Our previous study
also confirmed that Fasudil treatment ameliorated memory
deficits in APP/PS1 transgenic mice, accompanied by a
decrease in Aβ deposits, p‑Tau and BACE levels, an increase
in PSD‑95, and inhibition of the TLRS‑NF‑ κ B‑MyD88
inflammatory cytokine axis (24).
Although previous studies have demonstrated certain
beneficial effects of Fasudil intervention in the AD model (24),
several lines of evidence suggest that there are some limitations in the clinical use of Fasudil, including its suitability only
for short‑course treatment, low oral bioavailability, a narrow
safety window and blood pressure fluctuation. Thus, novel
ROCK inhibitor(s) that are more efficient, safer, oral and suitable for long‑term use for the treatment of neurodegenerative
disorders are required. In the present study, we explored the
therapeutic effect and systemic response of a novel ROCK
inhibitor, FSD‑C10, and possible mechanisms of its action in
the treatment of a mouse model of AD.
Materials and methods
Animals and treatment. Experiments were performed on
male APP/PS1 double transgenic mice (APPswe/PS1dE9,
8‑month‑old), purchased from Shanghai Research Center.
Age‑matched wild‑type (WT) mice were used as controls.
All animals were housed in a room maintained at 25˚C with
a 12‑h light/dark cycle. The mice were given free access to
food and water except during the behavioral test. The experiment was carried out in compliance with the Guidelines for
Animal Care and Use of China, and approved by the Animal
Ethics Committee of Shanxi Datong University, Datong,
China (Ethical Approval no. 1601). Every effort was made to
minimize suffering of the animals.
The experimental design was carried out in two stages:
Validation of the AD model and intervention of the AD model.
For validation of the AD model, mice were divided into two
groups: Age‑matched wild‑type (n=8) and APP/PS1 transgenic mice (n=8). Mice were sacrificed at 8 months of age.
Behavioral and pathological changes were measured before
and after execution. For the intervention of FSD‑C10, mice
were divided into two groups: Normal saline (NS)‑control
mice (n=8) and FSD‑C10‑treated mice (n=8). Mice were

treated with FSD‑C10 (25 mg/kg/day every other day) or NS
(0.9% NaCl) for 2 months by intraperitoneal (i.p.) injection.
The concentration of FSD‑C10 used in this study was adopted
based on our preliminary experiments.
Mouse spatial learning and memory test. Spatial learning
and memory of mice were assessed using the Morris water
maze (MWM) test. The MWM is a 90 cm high, 50 cm diameter circular pool, containing a submerged escape platform
(5.0x5.0 cm), 2.0 cm below the water surface. The pool was
filled with water containing an edible white pigment that made
the water opaque, and the water temperature was maintained
at 23‑25˚C. In each trial, the time required to escape onto the
hidden platform was recorded as escape latency. Mice were
allowed a maximum of 60 sec to reach the platform, and if
they failed to do so, they were guided to the platform. After
training was completed, cognitive function was measured for
5 days, after which the platform was removed for spatial exploration in order to determine the memory capacity of the mouse
as to the platform space position. All behavioral parameters of
mice were tracked, recorded and analyzed using SMART 3.0
(Panlab, Barcelona, Spain).
Histopathology and immunohistochemistry. At the end of the
final behavioral test, mice were anesthetized and transcardially
perfused with NS and 4% paraformaldehyde in phosphate‑buffered saline (PBS). Brains were sliced (10 µm) and analyzed by
immunohistochemistry. Briefly, slides were blocked with 1%
BSA (Sigma) for 1 h, and permeated with 0.3% Triton X‑100 in
1% BSA/PBS for 30 min at RT. Sections were incubated with
anti‑Aβ1‑42 (1:1,000; EMD Millipore, Billerica, MA, USA),
anti‑p‑Tau (1:1,000; Cell Signaling Technology, Inc., Danvers,
MA, USA), anti‑BACE (1:1,00; Cell Signaling Technology,
Inc.), anti‑synaptophin (1:1,000), anti‑AMPAR‑1 (1:1,000),
anti‑AMPAR‑2 (1:1,000; all from Abcam, Cambridge, MA,
USA), anti‑BDNF (1:1,000; Promega Corporation, Madison,
WI, USA), and anti‑GDNF (1:1,000; Promega Corporation) at
4˚C overnight. After washing, the slices were incubated with
secondary antibodies at RT for 2 h. The nucleus was stained
by Hoechst 33342 (1 µg/ml, Sigma‑Aldrich; Merck KGaA,
Darmstadt, Germany). Control sections were run following
identical protocols, but the primary antibodies were omitted.
Results were visualized under fluorescence microscopy by
IMAGE‑PRO PLUS software (Media Cybernetics, Inc.,
Rockville, MD, USA). Quantification analysis of positive cells
was performed on three sections per animal, and four mice per
group were analyzed in a blinded fashion.
Western blot analysis. Proteins of mouse brain were extracted
as previously described (17), Protein concentrations were
determined by a bicinchoninic acid (BCA) kit (Beyotime
Institute of Biotechnology, Haimen, China). Protein samples
were separated by SDS‑PAGE and transferred onto PVDF
membranes. After nonspecific binding was blocked with 5%
nonfat dry milk, membranes were incubated at 4˚C overnight
with primary antibodies (A β1‑42, p‑Tau, BACE, PSD‑95,
AMPAR‑1, AMPAR‑2, BDNF, GDNF and β‑actin). The next
day, the membranes were washed three to four times with
0.1% Tween‑20/TBST (pH 7.6) and incubated with horseradish peroxidase‑conjugated anti‑rabbit IgG or anti‑mouse
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Figure 1. AD transgenic mouse model. At 8 months of age, learning and memory ability was measured by the Morris Water Maze. (A) Compared with the
WT group, APP/PS1 transgenic mice exhibited obvious space learning and memory impairment. (B) At the same time, expression of Aβ1‑42, p‑Tau and BACE
protein was increased as measured by western blot. The results suggest that APP/PS1 mice showed typical behavior dysfunction and and typical pathologic
abnormality of AD. Results are expressed as the fold change relative to β‑actin as the loading control. Quantitative results are shown as mean ± SEM of 4 mice
each group. *P<0.05 and **P<0.01 vs. Wild-type. AD, Alzheimer's disease.

IgG secondary antibodies for 2 h at 37˚C. To compare protein
loading, antibodies directed against GAPDH or β‑actin were
used and relative optical density was measured with Image Lab
Software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Statistical analysis. Graph Pad Prism 5 (Cabit Information
Technology Co., Ltd., Shanghai, China) was used for statistical
analysis. Results are presented as mean ± SEM. An unpaired,
two‑tailed Student's t‑test was used for comparisons of means
between two groups. In all tests, P<0.05 was considered to
indicate a statistically significant difference.
Results
Behavioral and pathological changes in APP/PS1 mice
at 8 months of age. To observe the effect of FSD‑C10 in
APP/PS1 transgenic mice, we first tested the behavioral and
pathological changes at the initiation time of drug intervention
as a baseline. Memory and learning ability was measured by
MWM and the expression of Aβ1‑42, p‑Tau and BACE protein
was determined by western blot. As shown in Fig. 1, APP/PS1
transgenic mice exhibited obvious space learning and memory
impairment at 8 months of age, as compared with the WT
group. Simultaneously, the levels of Aβ1‑42, p‑Tau and BACE
expression were more elevated in APP/PS1 transgenic mice
than in the WT group (P<0.01, P<0.05 and P<0.05, respectively; Fig. 1B). Together, APP/PS1 mice showed the typical
behavior dysfunction and typical pathologic abnormality of
AD, thus confirming the AD model in these transgenic mice.
FSD‑C10 improves learning and memory abilities of the
APP/PS1 Tg mice. As shown in Fig. 1, APP/PS1 transgenic
mice had obvious space learning and memory impairment at

8 months of age compared with the WT group. To observe
whether FSD‑C10 can ameliorate the deficit in learning and
memory ability, MWM measurement was used in APP/PS1
mice after 2 months of treatment (Fig. 2A and B). As shown
in Fig. 2C, FSD‑C10 intervention significantly reduced the
time and distance for Latency to Target (P<0.01), Latency
1st Entrance to SW (P<0.05), and mean distances to Target
(P<0.05) of these AD mice.
When the platform was moved, a consolidation of spatial
memory was detected. The results showed that the movement of
FSD‑C10‑treated mice mainly located on the position of the target
platform quadrant, while NS‑controlled mice mainly moved
around the location of the target platform quadrant (Fig. 2A and B).
The intervention of FSD‑C10 increased Time in SW (P<0.01;
Fig. 2C) and Distance in SW (P<0.05; Fig. 2C) as compared
with the NS control group. However, there were no differences in
global activity between two groups (P>0.05; Fig. 2C).
FSD‑C10 attenuates A β burden, Tau phosphorylation and
BACE expression. We evaluated the pathological changes
in APP/PS1 transgenic mice, including A β plaques, Tau
phosphorylation and BACE expression by immunohistochemistry and western blot. As shown in Fig. 3A, the numbers of
Aβ1‑42‑positive cells in the hippocampus and cortex of brain
were lower in FSD‑C10‑treated mice than in NS‑treated control
mice. Similarly, FSD‑C10 intervention suppressed A β1‑42
protein level in brain when compared with the NS‑treated
control group (P<0.01; Fig. 3B).
We further explored the levels of p‑tau and BACE proteins
in the hippocampus and cortex with immunohistochemistry
and western blot. The results showed that the numbers of
p‑Tau and BACE positive cells were significantly lower in
FSD‑C10‑treated group than in the NS‑treated control group
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Figure 2. FSD‑C10 improves behavioral deficits of APP/PS1 Tg mice. Cognitive ability was analyzed in a Morris water maze test. The Morris water maze test
began two months after NS/FSD‑C10 administration. (A) 8‑zone Morris water maze schematic diagram, (B) typical diagram of two groups, and (C) Latency to
Target, Latency 1st Entrance to SW, Mean Distances to Target, Time in SW (%), Distance in SW and Global Activity (%). Results are shown as mean ± SEM
of 8 mice each group. *P<0.05 and **P<0.01 vs. APP/PS1+NS.

(P<0.05 and P<0.01 for p‑Tau; P<0.05 and P<0.05 for BACE;
Fig. 4A). Similarly, FSD‑C10 treatment inhibited the expression of p‑Tau and BACE protein in brain when compared
with the NS‑treated control mice (P<0.05; Fig. 4B). These
results suggest that FSD‑C10 treatment effectively alleviated
pathological changes in AD mice.
FSD‑C10 induces the expression of synapse‑associated
proteins. It has become clear that cognitive dysfunction more
strongly correlates with synapse loss in AD than with counts of
plaques, tangles, and neuronal loss (25,26). Our results showed
that FSD‑C10 treatment up‑regulated synaptophsin expression
in the hippocampus (P<0.01; Fig. 5A) as well as AMPAR‑1
and AMPAR‑2 expression in the cortex (P<0.01 and P<0.05,
respectively; Fig. 5A) as compared with NS‑treated control
mice. Data from western blot also confirmed that FSD‑C10
treatment up‑regulated the expression of AMPAR‑1 and
AMPAR‑2 protein in brain (both P<0.01; Fig. 5B).
PSD‑95 is a synaptic protein that regulates synaptic distribution, synaptic stability and certain types of memory (27).
As shown in Fig. 5B, FSD‑C10 treatment elevated the level of
PSD‑95 expression in brain as compared with the NS‑treated
control group (P<0.05; Fig. 5B). These results indicate that the
improvement in learning and memory impairment mediated

by FSD‑C10 may be related to the up‑regulation of these
synapse‑associated proteins in both hippocampus and cortex.
FSD‑C10 increases the expression of neurotrophic factors.
Neurotrophic factors are well known to be important for
the survival, differentiation, growth and regeneration of
neurons (28), as well as for synaptic transmission and plasticity (29). In this research, we explored the role of FSD‑C10
in production of neurotrophic factors. Immunohistochemical
analysis revealed that FSD‑C10 intervention increased the
numbers of both BDNF and GDNF positive cells in the hippocampus and cortex of brain compared with the NS‑treated
control group (P<0.01 and P<0.05 respectively; Fig. 6A).
Expression of BDNF and GDNF protein was also higher in
FSD‑C10‑treated mice than in the NS‑treated control group
measured by western blot (both P<0.05; Fig. 6B). FSD‑C10
thus has a potentially neuroprotective effect through the
production of neurotrophic factors.
Discussion
AD is an age‑related and chronic neurodegenerative disorder
presenting as progressive cognitive decline. Although the exact
pathogenesis is not yet clear, multiple etiologic pathways have
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Figure 3. FSD‑C10 attenuates Aβ1‑42 burden in hippocampus and cortex in APP/PS1 Tg mice. Aβ1‑42 was measured by immunohistochemistry and western
blot on two months after FSD‑C10 administration. (A) Aβ1‑42 expression was measured in hippocampus and cortex by immunohistochemistry and (B) in brain
tissue by western blot. Quantitative results are shown as mean ± SEM of 4 mice each group, and one representative of three independent experiments. *P<0.05
and **P<0.01 vs. APP/PS1+NS.

been considered (2). The major histopathological hallmarks
of AD include Aβ plaques and neurofibrillary tangles (NFTs)
formed by hyperphosphorylated Tau protein (30), and the
neurite atrophy and synaptic loss induced by Aβ are considered
to be the major cause of gradual cognitive detetrioration in
AD (31). Neurotoxicity of Aβ becomes apparent via induction
of oxidative stress, neuronal excitotoxicity, neuroinflammation
and apoptosis (32,33). One of the most promising strategies
for treatment of AD is to directly target Aβ by decreasing the

production and clearing aggregation of Aβ (34). In addition
to A β accumulation, tau hyperphosphorylation is also an
important pathological hallmark of AD (35). Abnormal phosphorylation of tau protein promotes the loss of microtubule
stabilizing ability and may contribute to neurite degeneration
as well as NFT formation (36). Current drugs for AD treatment,
such as acetylcholinesterase inhibitor and NMDA antagonist,
show limited benefits in most AD patients (37). There is thus
an urgent need for novel therapeutic strategies that can halt the
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Figure 4. FSD‑C10 reduces Tau phosphorylation and BACE expression in hippocampus and cortex in APP/PS1 Tg mice. p‑Tau and BACE were measured by
immunohistochemistry and western blot two months after FSD‑C10 administration. (A) The numbers of p‑Tau and BACE positive cells in hippocampus and
cortex were measured by immunohistochemistry and (B) their protein expression was measured in brain by western blot. Quantitative results are shown as
mean ± SEM of 4 mice each group, and one representative of three independent experiments. *P<0.05 and **P<0.01 vs. APP/PS1+NS.

disease process and are suitable for long‑term clinical management. In our previous studies, a comparative study of Fasudil
and FSD‑C10 has been reported, including cell viability, cell
death, neurite outgrowth and dendritic formation, vasodilation insensitivity and animal mortality (38). In this study, we
demonstrate that treatment with FSD‑C10, as a new ROCK
inhibitor, was able to reverse cognitive impairment, possibly
through decreasing Aβ accumulation and Tau phosphorylation
in the cortex and hippocampus of APP/PS1 transgenic mice.
A series of studies have demonstrated that ROCK was elevated
in the brain of AD patients compared to controls (39,40), and

inhibition of ROCK activity decreased Aβ levels by enhancing
APP protein degradation (41). Abnormal activation of ROCK
has also been found in AD experimental models, and may be
involved in the occurrence and development of diseases (41).
ROCK activation increased Aβ production, CRMP‑2 phosphorylation and hindered tubulin assembly, leading to the
inhibition of synapses (20,42). Inhibition of ROCK reduced the
production of Aβ (41) and increased the synaptic density and
length of hippocampal pyramidal neurons (43). Fasudil has
been proved to protect against nerve degeneration induced by
Aβ, and to improve spatial memory and learning ability in AD
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Figure 5. FSD‑C10 induces the expression of synaptophsin, AMPAR‑1, AMPAR‑2 and PSD‑95 protein in hippocampus or cortex in APP/PS1 Tg mice.
Synaptophsin, AMPAR‑1, AMPAR‑2 and PSD‑95 were measured by immunohistochemistry and western blot two months after FSD‑C10 administration.
(A) The numbers of synaptophsin, AMPAR‑1 and AMPAR‑2 positive cells in hippocampus or cortex were measured by immunohistochemistry; (B) their
protein in brain was measured by western blot. Quantitative results are shown as mean ± SEM of 4 mice each group, and one representative of three independent experiments. *P<0.05 and **P<0.01 vs. APP/PS1+NS.

rats (44). Our present study provides further evidence that inhibiting ROCK activity can improve cognitive deficits in APP/PS1
transgenic mice.
In clinical practice, Fasudil has several limitations,
including a relatively narrow safety window, poor oral bioavailability, and unsuitability for long‑term use. Researchers are

looking for novel ROCK inhibitors that are more efficient and
safer, can be taken orally and over a long period of time for the
treatment of neurodegenerative disorders. We have in previous
studies found that FSD‑C10, as a novel ROCK inhibitor, has
the same therapeutic effect, but is safer than Fasudil (38). In
EAE, FSD‑C10 ameliorated the clinical severity of disease,
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Figure 6. FSD‑C10 promotes the expression of neurotrophic factors in hippocampus or cortex in APP/PS1 Tg mice. The expression of BDNF and GDNF
protein was measured by immunohistochemistry and western blot two months after FSD‑C10 administration. (A) The numbers of BDNF and GDNF positive
cells in hippocampus and cortex by immunohistochemistry; and (B) their protein expression in brain by western blot. Quantitative results are shown as
mean ± SEM of 4 mice each group, and one representative of three independent experiments. *P<0.05 and **P<0.01 vs. APP/PS1+NS.

accompanied by improvement in demyelination and the inhibition of inflammatory cells in the CNS of EAE mice, clearly
showing a therapeutic effect (45).
Glutamate, the major excitatory neurotransmitter in the
CNS, is involved in synaptic transmission, neuronal growth
and differentiation, synaptic plasticity and learning and
memory (46). When a neuron is depolarized, glutamate is
released into the synaptic cleft where it binds glutamate
receptors (47). Glutamate receptors, such as NMDA receptor
and AMPA receptor, are involved in rapid excitatory synaptic
transmission and the release of neurotransmitters, which
is closely related with learning and memory (48). In the
postsynaptic membrane, an AMPAR insert can induce and
promote learning and memory behavior. Aβ‑induced decline
in AMPAR number and synaptic function through endocytosis is a plausible mechanism for the cognitive impairment
that occurs in the very early stages of AD (49). Further study

found that lack of AMPAR can cause dendritic spine reduction and loss of NMPAR (50), both of which are related to
cognitive impairment. In our study, increased expression of
AMPAR, synaptophsin and PSD‑95 protein after FSD‑C10
administration could be an important mechanism for the
improvement in cognitive function in transgenic APP/PS1
mice. PSD‑95 organizes synaptic proteins to mediate the
functional and structural plasticity of the excitatory
synapse and to maintain synaptic homeostasis (51). The
stabilization of a new synaptic protrusion is associated with
activity‑driven PSD proteinaceous network formation. In this
proteinaceous network, PSD‑95 is believed to play a role in
synapse maturation, given that it is particularly vulnerable
to the toxic effects of Aβ (28). Synaptophysin is the major
integral membrane protein of presynaptic vesicles required
for vesicle formation and exocytosis (52). Taken together,
FSD‑C10 may maintain the normal function of the synapse,
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possibly through promoting the expression of these synaptic
related proteins.
Neurotrophic factors play an essential role in the survival of
neurons affected by degenerative processes (53,54). Increased
levels of BDNF are associated with improved learning and
memory, and a reduction in BDNF leads to age‑related memory
deficits (55). The potential of GDNF against age‑related
cognitive deterioration has not been fully explored. It was
reported that serum GDNF levels were significantly reduced
in AD patients (56,57), and expression of GDNF transgene in
astrocytes improved cognitive deficits in aged rats (58). Thus,
increased BDNF, GDNF, AMPAR, PSD‑95, or synaptophysin
levels may reflect increased synaptic density, activity, and
vesicles, revealing improved functioning of synapses. Inducing
expression of these molecules could therefore be a mechanism underlying improved learning and memory abilities of
the APP/PS1 transgenic mice after FSD‑C10 treatment. The
limitations of this study may include that further mechanisms
underlying the inhibitory effect on Aβ after blocking ROCK
activity in AD remain unknown, and the oral effect of this
reagent in AD mice needs be tested. These questions will be
further explored in the near future.
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